Lazard Asset Management
AKYA

Lazard Asset Management’s Akoya BioSciences AKYA Stock Holding History

Lazard Asset Management’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,804
Closed -$36K – 2278
2022
Q4 		$36K Buy
+3,804
New +$46.8K ﹤0.01% 1944

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Lazard Asset Management's AKYA Position: Q1 2023 in Review

Lazard Asset Management sold out of Akoya BioSciences (AKYA) in Q1 2023, closing a stake of 3,804 shares — an estimated $36K sold.

Lazard Asset Management first reported a position in AKYA in Q4 2022 and held it in 1 quarter. The position peaked at $36K in Q4 2022. 63 funds tracked by Wall St. Rank hold AKYA as of Q1 2023.

  • Lazard Asset Management reported no remaining Akoya BioSciences position as of Q1 2023 after selling out during the quarter.
  • Lazard Asset Management sold 3,804 Akoya BioSciences shares in Q1 2023, an estimated $36K.
  • Lazard Asset Management first reported a position in Akoya BioSciences in Q4 2022 and held it in 1 quarter.
  • Lazard Asset Management's Akoya BioSciences position peaked at $36K in Q4 2022.
  • 63 funds tracked by Wall St. Rank held Akoya BioSciences as of Q1 2023.

Based on Lazard Asset Management's 13F filing for Q1 2023, filed 15 May 2023.